GlassScriptPhysician profile
Attica Chang
NPI 1225099781
$6,805.83
in general payments reported to CMS, 2019-2025
26 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $518 · 2021: $745 · 2022: $907 · 2023: $1,016 · 2024: $1,409 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,283 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.80 |
| Education | $240.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $980.80 | 2020-2025 | Blu-U, Ilumya, Odomzo |
| Abbvie INC. | $948.83 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $677.74 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $591.82 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Regeneron Healthcare Solutions, INC. | $590.07 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $487.56 | 2019-2025 | |
| Merz North America, INC. | $486.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.40 | 2022-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $255.19 | 2019-2023 | |
| Incyte Corporation | $226.79 | 2021-2023 | Opzelura |
| Leo Pharma INC. | $223.84 | 2023-2025 | Adbry, Spevigo |
| Almirall LLC | $180.38 | 2019-2025 | Klisyri |
| Pfizer INC. | $134.68 | 2019-2025 | |
| Lilly USA, LLC | $122.40 | 2020-2025 | Ebglyss, Taltz |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $87.61 | 2019-2022 | |
| Amgen INC. | $73.82 | 2021-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $69.79 | 2020-2024 | Jublia, Arazlo, Cabtreo |
| Ucb, INC. | $68.59 | 2021-2025 | Bimzelx, Cimzia |
| Organogenesis INC. | $40.45 | 2021-2024 | |
| Dusa Pharmaceuticals, INC. | $39.88 | 2019 | |
| Dermira, INC. | $19.00 | 2020 | |
| Arcutis Biotherapeutics, INC. | $18.76 | 2025 | Zoryve |
| Epi Health, LLC | $15.63 | 2020 | |
| Sensus Healthcare, INC. | $15.00 | 2019 | |
| Icad, INC | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Attica Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.